ASCO GU 2019 Prostate Cancer

Viewing 1-20 of 43 articles

ASCO GU 2019: Pembrolizumab in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: Prevention of Symptomatic Skeletal Events with Denosumab: REDUSE Trial

ASCO GU 2019: Enzalutamide and ADT with Salvage Radiation in Men with High-Risk PSA Recurrent Prostate Cancer: The STREAM trial

ASCO GU 2019: A Comparison of Fluorocholine-PET/CT and Conventional Imaging in Prostate Cancer

ASCO GU 2019: Transitional Surrogate Endpoint for Survival in Phase II Trials for mCRPC - Assessment of Circulating Tumor Cell Number

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

ASCO GU 2019: TALAPRO-2: A Two-Part, Placebo-Controlled Phase III Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: The P-Value Debate: Lower Them or Leave Them?

ASCO GU 2019: Oligometastatic Disease: Tumor Board - Medical Oncologist Perspective by Silke Gillessen, MD

ASCO GU 2019: A Phase II Trial in Progress: Pamiparib, an Investigational PARP Inhibitor, in Patients with mCRPC and a Circulating Tumor Cell Homologous Recombination Deficiency Phenotype or BRCA Defects

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Radiation Oncologist Perspective by Gert de Meerleer, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board, A Radiation Oncologist Perspective by Bridget Koontz, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Medical Oncologist Perspective by Michael Morris, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Urologic Oncologist Perspective by Edward Schaeffer, MD

ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC

ASCO GU 2019: Updated Analysis of Progression-Free Survival with First Subsequent Therapy and Safety in the SPARTAN Study of Apalutamide in Patients with High-Risk nmCRPC

ASCO GU 2019: Pembrolizumab Plus Olaparib Treatment for Docetaxel-Pretreated mCRPC Patients - KEYNOTE 365 Cohort A

ASCO GU 2019: Efficacy and Safety Data of the ARAMIS Study, Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Patients

ASCO GU 2019: LATITUDE Study - Final Analysis of Phase III Study in Patients with Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer

ASCO GU 2019: A Phase II, Open-label, Multi-arm Study of TAS-115 for Castration-resistant Prostate Cancer Patients with Bone Metastases

1
2
3

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.